An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
Public ClinicalTrials.gov record NCT00761774. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study. The study will explore the long-term safety and efficacy of brivaracetam.
Study identification
- NCT ID
- NCT00761774
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2008
- Primary completion
- Feb 28, 2017
- Completion
- Feb 28, 2017
- Last update posted
- Jul 10, 2018
2008 – 2017
United States locations
- U.S. sites
- 25
- U.S. states
- 18
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 304 | Phoenix | Arizona | — | — |
| 281 | Fresno | California | — | — |
| 288 | Pasadena | California | — | — |
| 240 | Riverside | California | — | — |
| 245 | Sacramento | California | — | — |
| 285 | Peoria | Illinois | — | — |
| 224 | Indianapolis | Indiana | — | — |
| 266 | Lexington | Kentucky | — | — |
| 231 | Waldorf | Maryland | — | — |
| 278 | Burlington | Massachusetts | — | — |
| 270 | New York | New York | — | — |
| 284 | Hickory | North Carolina | — | — |
| 241 | Columbus | Ohio | — | — |
| 265 | Oklahoma City | Oklahoma | — | — |
| 297 | Germantown | Tennessee | — | — |
| 260 | Austin | Texas | — | — |
| 236 | Bedford | Texas | — | — |
| 267 | Dallas | Texas | — | — |
| 268 | Houston | Texas | — | — |
| 211 | Layton | Utah | — | — |
| 235 | Ogden | Utah | — | — |
| 218 | Burlington | Vermont | — | — |
| 279 | Danville | Virginia | — | — |
| 277 | Charleston | West Virginia | — | — |
| 213 | Marshfield | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00761774, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2018 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00761774 live on ClinicalTrials.gov.